Trial Profile
Finding the Right Tenofovir/Emtricitabine Regimen for Pre-Exposure Prophylaxis (PrEP) in Transgender Women
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 17 Sep 2021
Price :
$35
*
At a glance
- Drugs Emtricitabine/tenofovir disoproxil fumarate (Primary)
- Indications HIV infections
- Focus Pharmacokinetics
- 17 Jul 2018 Status changed from recruiting to completed.
- 17 Apr 2018 Planned End Date changed from 31 Dec 2017 to 30 Jun 2018.
- 17 Apr 2018 Planned primary completion date changed from 31 Dec 2017 to 30 Jun 2018.